Salesforce
CRM
Oracle
ORCL
Coinbase
COIN
4
Microsoft
MSFT
5
Amazon
AMZN
US Stock MarketDetailed Quotes
RLMD Relmada Therapeutics
- 0.7426
- +0.0526+7.62%
Trading Apr 24 15:16 ET
24.65MMarket Cap-0.28P/E (TTM)
0.7537High0.5409Low5.21MVolume0.6194Open0.6900Pre Close3.40MTurnover17.03%Turnover RatioLossP/E (Static)33.19MShares4.470052wk High0.69P/B22.70MFloat Cap0.240452wk Low--Dividend TTM30.57MShs Float54.0000Historical High--Div YieldTTM30.84%Amplitude0.2404Historical Low0.6530Avg Price1Lot Size
Relmada Therapeutics Key Stats
EPS
According to the latest financial report of Relmada Therapeutics, the latest earnings per share (TTM) for the company is -0.62. Investing in companies with strong earnings per share can potentially provide higher returns.
Currency: USD
Quarterly
Loading...
FCF
Interested in knowing about Relmada Therapeutics's free cash flow? The latest report shows it as -8.80M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
Currency: USD
Quarterly
Loading...
Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Relmada Therapeutics shows that the company's current ratio is 4.45, indicating healthy liquidity.
Currency: USD
Quarterly
Loading...
Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Relmada Therapeutics, the quick ratio is 4.36, indicating that the company can meet its short-term debt obligations.
Currency: USD
Quarterly
Loading...
ROE
Want to learn more about the financial health of Relmada Therapeutics? The latest ROE figure is -44.88%, indicating that the company has stable profitability.
Currency: USD
Quarterly
Loading...
ROA
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Relmada Therapeutics, the total asset return on investment (ROA) is -36.75%.
Currency: USD
Quarterly
Loading...
Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Relmada Therapeutics's latest financial report to see how their gross margin is doing - currently at -0.44%.
Currency: USD
Quarterly
Loading...
Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Relmada Therapeutics, the net profit margin is -458.06%, which is a good sign for its profitability.
Currency: USD
Quarterly
Loading...
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call